Document Detail


Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology-findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study.
MedLine Citation:
PMID:  22137073     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness.
METHODS: HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points.
RESULTS: There was no interaction between etiology and treatment for the primary outcome (P = .73), cardiovascular (CV) mortality or CV hospitalization (P = .59), or CV mortality or HF hospitalization (P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality (P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors (P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization.
CONCLUSION: Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.
Authors:
David J Whellan; Anil Nigam; Malcolm Arnold; Aijing Z Starr; James Hill; Gerald Fletcher; Stephen J Ellis; Lawton Cooper; Anekwe Onwuanyi; Bleakley Chandler; Steven J Keteyian; Greg Ewald; Andrew Kao; Mihai Gheorghiade
Related Documents :
6439173 - Metabolic and respiratory effects of continuous and discontinuous lipid infusions. occu...
22116573 - Effects of load and training modes on physiological and metabolic responses in resistan...
9451623 - Stretch-shorten cycle compared with isometric preload: contributions to enhanced muscul...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  American heart journal     Volume:  162     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-05     Completed Date:  2012-03-01     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1003-10     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2011 Mosby, Inc. All rights reserved.
Affiliation:
Jefferson University College of Medicine, Philadelphia, PA 19107, USA. david.whellan@jefferson.edu
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00047437
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Exercise Therapy*
Female
Heart Failure, Systolic / etiology,  therapy*
Humans
Male
Middle Aged
Severity of Illness Index
Treatment Outcome
Ventricular Dysfunction, Left
Grant Support
ID/Acronym/Agency:
5U01-HL063747/HL/NHLBI NIH HHS; 5U01-HL066461/HL/NHLBI NIH HHS; HL064250/HL/NHLBI NIH HHS; HL064257/HL/NHLBI NIH HHS; HL064264/HL/NHLBI NIH HHS; HL064265/HL/NHLBI NIH HHS; HL066482/HL/NHLBI NIH HHS; HL066491/HL/NHLBI NIH HHS; HL066494/HL/NHLBI NIH HHS; HL066497/HL/NHLBI NIH HHS; HL066501/HL/NHLBI NIH HHS; HL068973/HL/NHLBI NIH HHS; HL068980/HL/NHLBI NIH HHS; U01 HL063747/HL/NHLBI NIH HHS; U01 HL063747-01A2/HL/NHLBI NIH HHS; U01 HL063747-02/HL/NHLBI NIH HHS; U01 HL063747-03/HL/NHLBI NIH HHS; U01 HL063747-04/HL/NHLBI NIH HHS; U01 HL063747-05/HL/NHLBI NIH HHS; U01 HL063747-06/HL/NHLBI NIH HHS; U01 HL063747-06S1/HL/NHLBI NIH HHS
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmaco...
Next Document:  Treadmill testing improves survival prediction models in pulmonary arterial hypertension.